The CDC has named Cepheid one of four national collaborators to accelerate rapid diagnostic assay development for public health emergencies under a new federal initiative and IDIQ contract.
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
The G4X system can analyze 128 samples per run with 500-plex RNA and 18-plex protein capabilities, targeting translational research and clinical applications.
The automation-compatible system works with plasma, serum, urine and cerebrospinal fluid samples from 1 ml to 4 ml input volumes.
The FDA has granted Breakthrough Device Designations to two 15-minute rapid tests for detecting Candida auris and carbapenem-resistant Acinetobacter baumannii, both identified by WHO as critical priority pathogens.
